1-5 of 5
Patrick Gagnon-Sanschagrin
Close
Sort by
Journal Articles

Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective

George J Joseph, Dominick Latremouille-Viau, Vikash Kumar Sharma, Patrick Gagnon-Sanschagrin, Menaka Bhor, PhD, Ankur Khare, Mukesh Kumar Singh, Elizabeth Serra, Mikhail Davidson, Annie Guerin, Nirmish Shah
Journal: Blood
Blood (2019) 134 (Supplement_1): 3464.
https://doi.org/10.1182/blood-2019-124920
Published: 2019
Journal Articles

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Karen Seiter, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Briana Ndife, MPH, Karen Habucky, PhD, George J Joseph, BPharm, MS, PhD, Irina Pivneva, PhD, Patrick Gagnon-Sanschagrin, MS, Derek H Tang, BSPharm, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3391.
https://doi.org/10.1182/blood.V130.Suppl_1.3391.3391
Published: 2017
Journal Articles

Reduction in Healthcare Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia (CML) with Better Adherence to Tyrosine Kinase Inhibitors (TKIs) and Increased Molecular Monitoring Frequency

Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Patrick Gagnon-Sanschagrin, BSc, Katherine Dea, MSc, Benjamin Cohen, MPH, George J Joseph, BPharm, MS, PhD
Journal: Blood
Blood (2016) 128 (22): 2398.
https://doi.org/10.1182/blood.V128.22.2398.2398
Published: 2016
Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Eytan M. Stein, MD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Sherry Shi, MSc, Patrick Gagnon-Sanschagrin, BSc, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD
Journal: Blood
Blood (2016) 128 (22): 5929.
https://doi.org/10.1182/blood.V128.22.5929.5929
Published: 2016
Journal Articles

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Lei Chen, MD PhD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Roy Nitulescu, MSc, Patrick Gagnon-Sanschagrin, BSc
Journal: Blood
Blood (2015) 126 (23): 1596.
https://doi.org/10.1182/blood.V126.23.1596.1596
Published: 2015